MXPA02011081A - Proteinas de subunidad de receptor de citocina de mamifero, reactivos y metodos relacionados. - Google Patents

Proteinas de subunidad de receptor de citocina de mamifero, reactivos y metodos relacionados.

Info

Publication number
MXPA02011081A
MXPA02011081A MXPA02011081A MXPA02011081A MXPA02011081A MX PA02011081 A MXPA02011081 A MX PA02011081A MX PA02011081 A MXPA02011081 A MX PA02011081A MX PA02011081 A MXPA02011081 A MX PA02011081A MX PA02011081 A MXPA02011081 A MX PA02011081A
Authority
MX
Mexico
Prior art keywords
polypeptide
leu
ser
seq
thr
Prior art date
Application number
MXPA02011081A
Other languages
English (en)
Spanish (es)
Inventor
Robert A Kastelein
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22753958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02011081(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA02011081A publication Critical patent/MXPA02011081A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
MXPA02011081A 2000-05-10 2001-05-10 Proteinas de subunidad de receptor de citocina de mamifero, reactivos y metodos relacionados. MXPA02011081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20342600P 2000-05-10 2000-05-10
PCT/US2001/015057 WO2001085790A2 (en) 2000-05-10 2001-05-10 Mammalian cytokine receptor subunit proteins, related reagents and methods

Publications (1)

Publication Number Publication Date
MXPA02011081A true MXPA02011081A (es) 2003-03-10

Family

ID=22753958

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011081A MXPA02011081A (es) 2000-05-10 2001-05-10 Proteinas de subunidad de receptor de citocina de mamifero, reactivos y metodos relacionados.

Country Status (25)

Country Link
US (7) US6756481B2 (enExample)
EP (3) EP1918377B1 (enExample)
JP (6) JP5073909B2 (enExample)
KR (1) KR100869621B1 (enExample)
CN (2) CN1575337A (enExample)
AT (1) ATE396264T1 (enExample)
AU (2) AU2001261351B2 (enExample)
CA (1) CA2408571C (enExample)
CY (1) CY1108545T1 (enExample)
CZ (1) CZ304022B6 (enExample)
DE (1) DE60134136D1 (enExample)
DK (1) DK1287130T3 (enExample)
ES (1) ES2307618T3 (enExample)
HK (1) HK1049862B (enExample)
HU (1) HUP0302339A3 (enExample)
IL (2) IL152414A0 (enExample)
MX (1) MXPA02011081A (enExample)
NO (2) NO331408B1 (enExample)
NZ (1) NZ522146A (enExample)
PL (1) PL209128B1 (enExample)
PT (1) PT1287130E (enExample)
SI (1) SI1287130T1 (enExample)
SK (1) SK287984B6 (enExample)
WO (1) WO2001085790A2 (enExample)
ZA (1) ZA200208795B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
ES2254224T3 (es) * 1999-09-27 2006-06-16 Chugai Seiyaku Kabushiki Kaisha Nueva proteina del receptor de hematopoyetina, nr12.
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
MXPA05004512A (es) * 2002-10-30 2005-07-26 Genentech Inc Inhibicion de la produccion de il-17.
WO2004058178A2 (en) 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
JP4605798B2 (ja) * 2003-03-10 2011-01-05 シェーリング コーポレイション Il−23アゴニストおよびil−23アンタゴニスト;関連試薬の使用
JP2007515939A (ja) * 2003-05-09 2007-06-21 セントカー・インコーポレーテツド IL−23p40特異的免疫グロブリン由来タンパク質、組成物、方法および用途
CN1942201B (zh) * 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法;相关试剂
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
AU2005241020B2 (en) * 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
TWI363091B (en) * 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
ES2410406T3 (es) 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anticuerpos anti-IL-23, composiciones, procedimientos y usos
EP3219328B1 (en) 2005-12-29 2020-06-17 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, method and uses
MY157796A (en) 2006-06-08 2016-07-29 Chugai Pharmaceutical Co Ltd Preventive or remedy for inflammatory disease
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
AU2008219681A1 (en) * 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
CA2679381A1 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
CN101939025B (zh) 2007-12-05 2015-03-25 中外制药株式会社 搔痒症治疗药
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
EA201101572A1 (ru) * 2009-04-27 2012-05-30 Новартис Аг Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
EP2635601B1 (en) 2010-11-04 2016-07-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
WO2013165791A1 (en) 2012-05-03 2013-11-07 Boehringer Ingelheim International Gmbh Anti-il-23p19 antibodies
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
US10059763B2 (en) 2014-09-03 2018-08-28 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and TNF-alpha and uses thereof
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
BR112022023489A2 (pt) 2020-05-21 2023-03-14 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5888774A (en) 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
JPH11273358A (ja) 1998-03-26 1999-10-08 Kawasaki Steel Corp 半導体記憶装置
US20030082734A1 (en) 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
WO2000073451A1 (en) * 1999-06-01 2000-12-07 Schering Corporation Mammalian receptor proteins; related reagents and methods
IL148300A0 (en) * 1999-09-09 2002-09-12 Schering Corp Mammalian cytokines; related reagents and methods
JP2008099690A (ja) 1999-09-27 2008-05-01 Chugai Pharmaceut Co Ltd 新規ヘモポエチン受容体蛋白質、nr12
ES2254224T3 (es) * 1999-09-27 2006-06-16 Chugai Seiyaku Kabushiki Kaisha Nueva proteina del receptor de hematopoyetina, nr12.
US6756481B2 (en) * 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions

Also Published As

Publication number Publication date
CA2408571A1 (en) 2001-11-15
EP1918377B1 (en) 2013-12-04
US20110243842A1 (en) 2011-10-06
IL152414A (en) 2010-05-31
JP5073909B2 (ja) 2012-11-14
US7510853B2 (en) 2009-03-31
PL209128B1 (pl) 2011-07-29
US7749718B2 (en) 2010-07-06
ZA200208795B (en) 2004-02-09
JP2015057396A (ja) 2015-03-26
NO331408B1 (no) 2011-12-19
US7411041B2 (en) 2008-08-12
CN1575337A (zh) 2005-02-02
WO2001085790A2 (en) 2001-11-15
SI1287130T1 (sl) 2008-08-31
US20090060865A1 (en) 2009-03-05
WO2001085790A3 (en) 2002-07-18
JP2015110576A (ja) 2015-06-18
EP1287130B1 (en) 2008-05-21
US6756481B2 (en) 2004-06-29
KR100869621B1 (ko) 2008-11-21
US20050100918A1 (en) 2005-05-12
NZ522146A (en) 2004-10-29
PT1287130E (pt) 2008-09-01
US20100261273A1 (en) 2010-10-14
NO20025354L (no) 2003-01-10
US20050100917A1 (en) 2005-05-12
PL365177A1 (en) 2004-12-27
SK15742002A3 (sk) 2003-03-04
CA2408571C (en) 2014-04-29
JP2003532408A (ja) 2003-11-05
AU2001261351B2 (en) 2007-03-01
IL152414A0 (en) 2003-05-29
EP1287130A2 (en) 2003-03-05
HUP0302339A2 (hu) 2003-10-28
US7964703B2 (en) 2011-06-21
HUP0302339A3 (en) 2011-01-28
CY1108545T1 (el) 2014-04-09
EP1287130B2 (en) 2017-07-26
US8110378B2 (en) 2012-02-07
NO20111147L (no) 2003-01-10
CZ20023698A3 (cs) 2003-04-16
CN101654479A (zh) 2010-02-24
JP2012187111A (ja) 2012-10-04
EP1918377A1 (en) 2008-05-07
ATE396264T1 (de) 2008-06-15
AU6135101A (en) 2001-11-20
NO20025354D0 (no) 2002-11-08
HK1049862A1 (en) 2003-05-30
US20120121601A1 (en) 2012-05-17
JP2012070740A (ja) 2012-04-12
ES2307618T3 (es) 2008-12-01
HK1049862B (en) 2008-08-01
DK1287130T3 (da) 2008-09-01
SK287984B6 (sk) 2012-08-06
CZ304022B6 (cs) 2013-08-28
US20030017617A1 (en) 2003-01-23
EP2275548A1 (en) 2011-01-19
JP2008273961A (ja) 2008-11-13
KR20020092472A (ko) 2002-12-11
DE60134136D1 (de) 2008-07-03

Similar Documents

Publication Publication Date Title
US7749718B2 (en) Method for raising or isolating an antibody to DCRS5
AU2001261351A1 (en) Mammalian receptor proteins; related reagents and methods
EP1181366B2 (en) Mammalian receptor proteins; related reagents and methods
US20050106673A1 (en) Mammalian receptor proteins; related reagents and methods
AU2007202362B2 (en) Mammalian receptor proteins; related reagents and methods
HK1117192A (en) Mammalian cytokine receptor subunit proteins, related reagents and methods
HK1152072A (en) Mammalian cytokine receptor subunit proteins, related reagents and methods

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status